



Minerva Access is the Institutional Repository of The University of Melbourne

**Author/s:**

Gascoyne, CR;Simpson, S;Chen, J;van der Mei, I;Marck, CH

**Title:**

Modifiable factors associated with depression and anxiety in multiple sclerosis

**Date:**

2019-01-01

**Citation:**

Gascoyne, C. R., Simpson, S., Chen, J., van der Mei, I. & Marck, C. H. (2019). Modifiable factors associated with depression and anxiety in multiple sclerosis. *Acta Neurologica Scandinavica*, 140 (3), pp.204-211. <https://doi.org/10.1111/ane.13132>.

**Persistent Link:**

<https://hdl.handle.net/11343/286038>

1

2 MS. CLAUDIA ROSE GASCOYNE (Orcid ID : 0000-0002-1241-4062)

3

4

5 Article type : Original Article

6

7

8 **Modifiable factors associated with depression and anxiety in multiple sclerosis**9 **Running Title:** Modifiable factors, depression and anxiety in MS

10

11 Gascoyne, Claudia R MSc<sup>1</sup>; Simpson, Jr., Steve PhD<sup>2,3</sup>; Chen, Jing MD<sup>3</sup>, van der Mei, Ingrid  
12 PhD<sup>3</sup>; Marck, Claudia H PhD<sup>1,2</sup>;13 <sup>1</sup>Disability and Health Unit, Melbourne School of Population and Global Health, The  
14 University of Melbourne15 <sup>2</sup>Centre of Epidemiology and Biostatistics, Melbourne School of Population and Global  
16 Health, The University of Melbourne17 <sup>3</sup>Menzies Institute for Medical Research, University of Tasmania.

18

19 **Corresponding Author:**

20 Claudia Gascoyne

21 Melbourne School of Population and Global Health

22 207 Bouverie St, The University of Melbourne, Victoria 3010, Australia

23 E-mail: claudiagascoyne@gmail.com

24 Telephone: +61 428 043 117

25

26 **Acknowledgements:** The authors thank all the participants in the Australian Multiple

27 Sclerosis Longitudinal Study for their support and willingness to complete the surveys.

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/ANE.13132](https://doi.org/10.1111/ANE.13132)

This article is protected by copyright. All rights reserved

## 28 ABSTRACT (225/250)

29 **Objectives:** Modifiable lifestyle factors are implicated in multiple sclerosis (MS) symptoms  
30 but their role in mood is unclear. This study aims to investigate associations between  
31 lifestyle and depression and anxiety in Australian participants with MS.

32 **Materials & Methods:** Self-reported data from the Australian Multiple Sclerosis  
33 Longitudinal Study included the Hospital Anxiety and Depression Scale (HADS) and lifestyle  
34 measurements from 1,500 participants. SNAP score (range 0-5) was the sum of: non-  
35 smoking, sufficient fruit/vegetable intake, non-hazardous alcohol consumption, sufficient  
36 physical activity, and healthy BMI. Analyses by log-binomial and linear regression were  
37 adjusted for confounding.

38 **Results:** Depression and anxiety was prevalent in 27% and 40%, respectively; 20% had  
39 both. Mean SNAP score was 2.7/5; only 3% met all healthy lifestyle recommendations. Only  
40 10% reported adequate fruit/vegetable intake, and 22% reported a combination of  
41 unhealthy BMI, inadequate physical activity and inadequate nutrition. A healthier SNAP  
42 score was associated with lower depression prevalence (adjusted prevalence ratio 0.83  
43 (95%CI 0.75, 0.92) per unit increase) and depression severity (adjusted  $\beta$  -0.44 (95%CI -  
44 0.64, -0.24)), but not with anxiety.

45 **Conclusions:** Modifiable lifestyle factors are associated with lower frequency and severity  
46 of depression, but not anxiety, in Australian people with multiple sclerosis. The  
47 associations between a healthier SNAP score and lower depression are likely bi-directional.  
48 SNAP risk factor prevalence and co-occurrence, especially inadequate nutrition and low  
49 physical activity, was high among Australians with MS.

50  
51 **Keywords:** multiple sclerosis; anxiety; depression; lifestyle; health behaviours; SNAP

## 52 53 INTRODUCTION

54 Clinically significant symptoms of anxiety or depression are observed in up to 40% of  
55 people with multiple sclerosis (MS)<sup>1</sup>, with prevalence estimates approximately twice that

56 of the general population<sup>2</sup>. It is possible that anxiety and depression arise from  
57 inflammation of the CNS and are hence considered symptoms of MS, yet they can also be  
58 considered comorbidities, secondary to the disease<sup>3</sup>. Both mood states have been  
59 associated with increased level of disability<sup>4</sup> and fatigue<sup>5</sup>. Stress responses associated with  
60 anxiety, as well as depressive symptoms, have been associated with increased  
61 inflammation and with exacerbations of MS<sup>6</sup>.

62  
63 Current pharmacological or psychological treatments for depression are proven to be  
64 generally effective in reducing clinically significant symptoms<sup>7</sup> in most people with MS.  
65 However, the effectiveness of anxiety treatments for people with MS has not been  
66 established<sup>7</sup>. Furthermore, only half of all people with MS suffering from anxiety or  
67 depression receive treatment for their condition<sup>2</sup>.

68  
69 Modifiable lifestyle factors such as smoking status, nutrition, alcohol consumption, physical  
70 activity level and body mass index (BMI) make up the 'SNAP' score, a construct used in  
71 general practice<sup>8</sup>. These SNAP factors are major determinants of morbidity, mortality, and  
72 functionality in the general population<sup>9</sup>. Growing evidence suggests that these same SNAP  
73 factors also play a major role in brain and mental health<sup>9</sup>. Whether there is an additive  
74 effect from fulfilling more of these SNAP factors is unclear, given that few studies have  
75 explored SNAP score in people with MS.

76  
77 The current study uses a representative sample of people with MS in Australia to 1)  
78 describe the prevalence of SNAP risk factors and their co-occurrence; 2) investigate  
79 whether SNAP score is associated with the prevalence and severity of anxiety and  
80 depression.

81

## 82 MATERIALS & METHODS

83 All data was sourced from the Australian Multiple Sclerosis Longitudinal Study (AMSLS).  
84 The sample is large, representative and generalisable to the Australian MS population<sup>10</sup>. To  
85 be eligible for the study, an individual must have a diagnosis of MS, be over 18 years of  
86 age, and live in any Australian state or territory. The study was approved by the Tasmanian  
87 Health and Medical Human Research Ethics Committee and all participants provided  
88 informed consent. The 2016 AMSLS Lifestyle survey was conducted from August to October  
89 2016. Invitations were sent to all 3112 active participants (2182 online surveys and 930  
90 paper surveys), and 1518 (48.78 %) participants responded to the survey (1067 online and  
91 451 paper surveys). Non-response analyses showed no significant difference in sex  
92 ( $p=0.101$ ) and education level ( $p=0.113$ ) between the respondents and non-respondents,  
93 while the respondents were slightly older (+1.49 years,  $p<0.01$ ) and had a slightly longer  
94 MS duration since diagnosis (+0.56 years,  $p=0.04$ ). These differing factors were included in  
95 multivariable models.

96

### 97 SNAP Score

98 SNAP – comprised of smoking, nutrition, alcohol and physical activity – was first proposed  
99 as part of a policy framework tool by the Australian Government in 2001 for use in general  
100 practice<sup>8</sup>. SNAP has previously been used in a North American sample of people with MS to  
101 estimate prevalence of lifestyle risk factors<sup>11</sup>. The five factors comprising the SNAP score in  
102 our study were modelled on this study<sup>11</sup> and another more recent study<sup>12</sup> both using  
103 similar aggregate scores, with minor deviations to suit the Australian SNAP guidelines. Our  
104 aggregate SNAP score included smoking status, diet (assessed by the Diet History  
105 Questionnaire, DHQ<sup>13</sup>), alcohol consumption, physical activity level (assessed by the  
106 International Physical Activity Questionnaire, IPAQ<sup>14</sup>), and BMI (estimated from self-  
107 reported height and weight, as weight (kg)/height (m)<sup>2</sup>), each coded as binary variables. To  
108 achieve a score for non-smoker, an individual had to report smoking less than one  
109 cigarette, cigar or pipe per day. A healthy diet was defined as consuming  $\geq 5$  serves of

110 vegetables/day and  $\geq 2$  serves of fruit at least six days/week, as per the Australian Dietary  
111 Guidelines<sup>15</sup>. Non-hazardous alcohol consumption required consuming  $\leq 2$  standard  
112 alcoholic drinks/day, the national recommendation<sup>16</sup>. Adequate level of physical activity  
113 was defined as moderate/high (versus low) level of physical activity as scored per the IPAQ  
114 guidelines<sup>14</sup>. A healthy BMI was defined as within the healthy BMI range (18.5 kg/m<sup>2</sup> to  
115 24.9 kg/m<sup>2</sup>) as opposed to underweight (below 18.5 kg/m<sup>2</sup>), overweight (25 kg/m<sup>2</sup> to 29.9  
116 kg/m<sup>2</sup>) or obese (30.0 kg/m<sup>2</sup> and above)<sup>17</sup>.

117

### 118 Anxiety and Depression

119 The Hospital Anxiety and Depression Scale (HADS)<sup>18</sup> was used to measure cognitive and  
120 emotional symptoms of anxiety and depression. The HADS has been validated for use in  
121 people with MS to measure depression and generalised anxiety<sup>19</sup>. The two subscales of the  
122 HADS, anxiety and depression, each had a range of 0-21 and were evaluated to assess  
123 associations with depression/anxiety severity. The HADS threshold for mild symptoms ( $\geq 8$ )  
124 was used to determine whether an individual showed clinically significant symptoms of  
125 anxiety or depression<sup>18</sup>.

126

127 Other data collected included age, sex, MS type, disability measured by the Patient-  
128 Determined Disease Steps (PDDS) scale<sup>20</sup>, fatigue measured by the Fatigue Severity Scale  
129 (FSS)<sup>21</sup>, disease duration since symptom onset, MS disease-modifying therapy use,  
130 treatment for depression or anxiety, number of previous or current comorbidities  
131 (including a list of 30 common chronic medical conditions and a “other” free text option),  
132 education level, employment status, remoteness, and socioeconomic status measured by  
133 the SEIFA Index of Relative Socioeconomic Advantage and Disadvantage (IRSAD)<sup>22</sup>.

134

### 135 Statistical Analyses

136 Associations with prevalent anxiety/depression were assessed using log-binomial  
137 regression, estimating a prevalence ratio. Associations with severity of anxiety and  
138 depression symptoms were assessed by linear regression. Polytomous independent

139 variables were evaluated as predictors of outcomes using log-binomial regression, the  
140 stratum-specific values using an interaction-expansion operator. For ordinal polytomous  
141 independent variables, in addition to the stratum-specific estimates of association, the  
142 regression was also run without the interaction expansion operator, thus evaluating the  
143 categorical term as a continuous variable. The significance of this association denoted the  
144 test for trend. All models were adjusted for age, sex, disability, fatigue, depression/anxiety  
145 treatment, education, and socioeconomic status. These confounders were identified via a  
146 directed acyclic graph (DAG), which was created using relevant literature according to best  
147 practice epidemiological methods<sup>23</sup>. All analyses were complete case analyses, meaning  
148 only those with complete SNAP, anxiety and depression data were included in analyses.  
149 Analyses were conducted using STATA 13.0 (StataCorp, College Station, USA).

150

## 151 RESULTS

152 1500 participants completed enough data to be included in this study. The majority of  
153 participants were female (79.5%), unemployed (60.4%), used disease-modifying therapies  
154 (62.4%) and had relapsing-remitting MS (61.9%) (Table 1). Almost half of the sample had a  
155 mild level of disability as defined by PDDS<3 (47.6%). Comorbidities were experienced by  
156 the vast majority of participants (91.1%), with some reporting more than ten  
157 comorbidities. Those with complete data were similar to those with incomplete data,  
158 except that those with incomplete data were more likely to be severely disabled and  
159 receiving treatment for depression (Table 1). Over one-third of participants had clinically  
160 significant symptoms of anxiety and roughly one-quarter had clinically significant  
161 symptoms of depression; one-fifth had both anxiety and depression.

162

163 [Insert Table 1 here]

164

165 SNAP Factors

166 Most participants did not smoke (89.6%) and reported alcohol consumption within  
167 recommended levels (82.9%; Table 2). Around 10% of the sample consumed the  
168 recommended daily intake of fruit and vegetables, with 33.1% meeting the fruit  
169 consumption targets and 17.0% meeting the vegetable consumption targets. Just over half  
170 of participants engaged in adequate physical activity (52.9%), while 39% had a healthy BMI.

171

172 [Insert Table 2 here]

173

174 SNAP Risk Factor Co-occurrence

175 The most common combination of SNAP risk factors was unhealthy BMI, inadequate  
176 physical activity and inadequate nutrition, observed in almost one-quarter of the  
177 participants (22.2%; Figure 1). Of those with just one SNAP risk factor, poor diet was the  
178 most common, with 14.0% meeting all other SNAP factor recommendations except for  
179 consumption of the recommended daily intake of fruit and vegetables.

180

181 [Insert Figure 1 here]

182

183 SNAP Protective Factor co-occurrence

184 Only 3.0% of the sample met all five SNAP protective factor recommendations, while 0.8%  
185 met none at all (Figure 1).

186

187 Anxiety and depression

188 Anxiety was less prevalent with increasing age, and more prevalent in females compared to  
189 males (Table 3). Participants with moderate or severe disability had a roughly 2-fold  
190 greater prevalence of depression, but for anxiety there was no consistent relationship with  
191 disability. Prevalent fatigue, however, was associated with a higher prevalence of anxiety  
192 and depression. Progressive-onset MS was associated with a greater prevalence of

193 depression compared to relapse-onset MS. Those with more comorbidities were more  
194 likely to have anxiety and depression. Education, employment and socioeconomic status  
195 were associated with lower prevalence of depression, but none were significantly  
196 associated with anxiety. Participants reporting anxiety and/or depression treatment were  
197 more likely to have anxiety and depression.

198

199 [Insert Table 3 here]

200

### 201 SNAP Protective Factors and Anxiety & Depression

202 Non-smokers and those engaging in adequate physical activity had lower prevalence of  
203 depression and lower HADS-Depression scores (Table 4). Participants who met the  
204 recommendations for healthy diet had lower HADS-Depression scores. Those who reported  
205 non-hazardous consumption of alcohol had a lower prevalence of depression. Non-  
206 smoking status was associated with a lower anxiety severity, but none of the other  
207 individual SNAP factors were associated with anxiety severity or prevalence.

208

209 [Insert Table 4 here]

210

211 Higher SNAP score showed a significant and dose-dependent inverse relationship with  
212 depression prevalence and severity, such that those with a SNAP score of 4-5 had 43%  
213 lower prevalence of depression and 1.57-points lower HADS-Depression score compared to  
214 those with a SNAP score of 0-1. When analyzing the SNAP score as a continuous variable,  
215 every unit increase in SNAP score was associated with a 17% reduction in prevalent  
216 depression and a 0.44 unit lower actual HADS depression score. While there was some  
217 indication of an inverse relationship between SNAP score and anxiety severity, this was of  
218 poor dose-dependency and did not reach statistical significance.

219

## 220 DISCUSSION

221 This study examined the association between an aggregate lifestyle score and depression &  
222 anxiety using data from a representative sample of people with MS in Australia. A healthier  
223 lifestyle, as measured by a higher SNAP score, was associated with a lower prevalence and  
224 severity of depression. No significant associations were observed with the prevalence and  
225 severity of anxiety.

226

227 Depression was common (27%) and associated with SNAP risk factors smoking, alcohol  
228 consumption and physical inactivity, while depression severity was associated with  
229 smoking, inadequate nutrition and physical inactivity. Every unit increase in SNAP score  
230 was associated with a 17% reduction in prevalent depression and a 0.44 unit lower actual  
231 HADS depression score. The findings are in line with previous work showing that smoking  
232 and poor diet were associated with increased risk of depression in people with MS<sup>24</sup>.

233 Research into the mechanisms between diet and mood is still emerging, but evidence for  
234 this association is strong within the general population<sup>25</sup>. Observational studies in people  
235 with MS have consistently shown an association between physical inactivity and  
236 depression<sup>26</sup> as well as excessive alcohol use and depression<sup>27</sup>, so our results here are in  
237 keeping with these prior findings. We did not find an association between BMI and  
238 depression prevalence or severity, however, which is inconsistent with previous  
239 studies<sup>24,28</sup>. This could reflect differences in study design or populations, however, this is  
240 mere speculation and more research is needed to clarify this.

241

242 The underlying mechanisms, and causality, of these associations cannot be disentangled  
243 from our data. On the one hand, research has shown that individuals experiencing clinically  
244 significant depression are more likely to engage in poor health behaviours<sup>29</sup> and may be  
245 less likely to have the motivation to engage in healthy lifestyle behaviours or be proactive  
246 about their health. Treating the depression may then also result in a reduction of  
247 modifiable risk factors, which may have flow-on effects for general health. However, on the  
248 other hand, a combination of lifestyle risk factors may also contribute to the risk for

249 depression. Modifying these risk factors may then also see a decrease in depression. Both  
250 mechanisms may be at play simultaneously and it is likely that for those with depression a  
251 feedback loop exists, whereby the risk for depression is increased by poor health  
252 behaviours, while depressive symptoms increase the risk for poor health behaviours, and  
253 so on. Sophisticated feedback loops for depression including health behaviours have been  
254 described in the literature<sup>30</sup>, and a further understanding of these may improve both  
255 depressive symptoms and health behaviours.

256

257 Anxiety was very common (40%) and anxiety symptom severity was associated with  
258 smoking, in line with a previous prospective study in people with MS<sup>31</sup>. However, no other  
259 associations were found between individual SNAP factors or SNAP score and anxiety  
260 prevalence or symptom severity. Far less is known about the association between anxiety  
261 and modifiable lifestyle factors in people with MS given that anxiety disorders are often  
262 overlooked and under-treated in this population<sup>2</sup>. One study found that people with MS  
263 who have a history of excessive alcohol consumption have a higher lifetime prevalence of  
264 anxiety<sup>32</sup> and another found that people with MS with obesity are more likely to have  
265 anxiety<sup>28</sup>. There is evidence that the SNAP protective factors are associated with anxiety in  
266 other populations, such as those with cardiovascular disease<sup>33</sup>.

267

268 We found that SNAP risk factors were common, in line with previous studies in the United  
269 States<sup>11,34</sup>. The vast majority of people with MS are not consuming the recommended daily  
270 requirement of fruit and vegetables (90%), with proper vegetable intake being the most  
271 infrequent. The proportions of people with MS who were overweight or obese (58%), had  
272 hazardous consumption of alcohol (17%) or smoked (10%), were similar to those of  
273 previous studies<sup>11</sup>. Interestingly, however, physical activity levels in this sample were  
274 slightly higher compared to a previous study<sup>11</sup>. Inadequate nutrition, physical inactivity  
275 and unhealthy BMI was the most common combination of SNAP risk factors (22%)<sup>11</sup>.

276

## 277 Strengths and Limitations

278 This study benefits from a large sample size and broad and validated representativeness,  
279 both to the general Australian population and particularly to the MS population.

280 Accordingly, the generalisability of these results is manifest. The comprehensive  
281 measurement of multiple demographic, clinical and lifestyle factors gives us great capacity  
282 to control for relevant confounding variables so as to assess the independence of the  
283 observed associations. A key limitation of the present analysis is its cross-sectional nature,  
284 thus precluding ascription of causal directionality. Likely there exists bi-directionality and  
285 further prospective cohort or randomised trial studies are needed to assess the causal  
286 direction of these associations, given that retrospective measures of modifiable lifestyle  
287 factors were not included as part of the current study.

288

289 The lack of association found between SNAP score and anxiety could be due to the fact  
290 that the HADS does not differentiate between different types of anxiety, but instead  
291 observes cognitive and emotional aspects of generalised anxiety<sup>19</sup>. The HADS measure may  
292 not have the specificity to detect other types of anxiety disorders, yet the association  
293 between SNAP score and anxiety and depression may differ between disorders.

294

295 All variables used in the analyses were self-reported, including all measures used for the  
296 SNAP score and the HADS. Due to the size of the study, it was not feasible to extract  
297 objective measures for every participant. This possibly introduced differential exposure  
298 measurement error, meaning that those with anxiety and/or depression may report their  
299 engagement in SNAP protective factors differently to those without anxiety and/or  
300 depression. Not enough is known about the direction of this bias to infer its effect on the  
301 association between SNAP protective factors and anxiety and depression. Selection bias  
302 may have resulted in an under-estimated prevalence of depression and/or anxiety, given  
303 that people with more severe symptoms of depression and/or anxiety may be less likely to  
304 participate in the survey. A recent relapse may have negatively impacted mood or  
305 engagement in modifiable lifestyle behaviours, however these data were not assessed. We

306 included number of comorbidities as an aggregate covariable, ensuring a wide range of  
307 common chronic medical conditions were included. Analyses of each comorbidity type was  
308 beyond the scope of this study.

309

#### 310 Implications of Findings

311 The high prevalence and co-occurrence of SNAP risk factors warrants increased health  
312 assessment and referrals by healthcare professionals, especially in people with MS and  
313 depression. It is likely that the presence of depressive symptoms will be accompanied by  
314 poor lifestyle behaviours, overweight or obesity. Anxiety and depression should be treated  
315 as separate and very unique constructs in this population, given their markedly different  
316 prevalence, as well as the diverse associations between SNAP score and anxiety and  
317 depression observed. Investigation of barriers faced by people with MS in improving health  
318 behaviours has identified fatigue, physical impairment and side effects of MS and  
319 associated medications<sup>35</sup> and these need to be assessed and addressed on an individual  
320 basis. The utility of the SNAP score may vary across the disease course. Longitudinal  
321 assessment of lifestyle modification among participants with greater and lesser degrees of  
322 disease severity would be informative.

323

#### 324 Conclusion

325 We found that SNAP protective factors and a healthier SNAP score were associated with a  
326 lower depression prevalence and severity, while no associations were seen for anxiety. The  
327 present study is the first to provide evidence that there is a high prevalence of anxiety and  
328 depression in a representative sample of Australian people with MS and that many are not  
329 meeting health recommendations. Investigation of the co-occurrence of SNAP risk factors  
330 in this population showed that a combination of unhealthy BMI, poor diet and inadequate  
331 physical activity is common. Given that SNAP risk factors, anxiety and depression all  
332 contribute significantly to the morbidity of MS, efforts to improve the lifestyle and mental  
333 health outcomes for an individual with MS should be holistic and all-inclusive. Future  
334 prospective studies should elucidate the direction of association between depression and

335 SNAP protective factors, alongside investigation of the viability of multi-modal lifestyle  
336 modification to treat depressive symptoms in this population.

337

#### 338 DECLARATION OF CONFLICTING INTERESTS

339 The authors declared no potential conflicts of interest with respect to the research,  
340 authorship and/or publication of this article.

341

#### 342 FUNDING

343 The authors disclosed receipt of the following financial support for the research,  
344 authorship and/or publication of this article:

345 This study was supported by Multiple Sclerosis Research Australia.

346 CM is funded by an Early Career Fellowship from the National Health and Medical Research  
347 Council (ID: 1120014).

348

#### 349 DATA AVAILABILITY STATEMENT

350 The data that support the findings of this study are not publicly available unless on specific  
351 request to the study investigators. Availability is conditional on approval of data sharing  
352 from the institutional ethics committee.

## REFERENCES

1. Suh Y, Motl RW, Mohr DC. Physical activity, disability, and mood in the early stage of multiple sclerosis. *Disability and Health Journal*. 2010;3(2):93-98.
2. Beiske A, Svensson E, Sandanger I, et al. Depression and anxiety amongst multiple sclerosis patients. *European Journal of Neurology*. 2008;15(3):239-245.
3. Feinstein A, Magalhaes S, Richard J-F, Audet B, Moore C. The link between multiple sclerosis and depression. *Nature Reviews Neurology*. 2014;10(9):507.
4. McKay KA, Tremlett H, Fisk JD, et al. Psychiatric comorbidity is associated with disability progression in multiple sclerosis. *Neurology*. 2018;90(15):e1316-e1323.
5. Chwastiak LA, Gibbons LE, Ehde DM, et al. Fatigue and psychiatric illness in a large community sample of persons with multiple sclerosis. *Journal of Psychosomatic Research*. 2005;59(5):291-298.
6. Burns MN, Nawacki E, Siddique J, Pelletier D, Mohr DC. Prospective examination of anxiety and depression before and during confirmed and pseudo-exacerbations in patients with Multiple Sclerosis. *Psychosomatic Medicine*. 2013;75(1):76.
7. Fiest KM, Walker JR, Bernstein CN, et al. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. *Multiple Sclerosis and Related Disorders*. 2016;5:12-26.
8. Harris M, Davies GP. SNAP: A journey from research to policy to implementation and back. *New South Wales Public Health Bulletin*. 2005;16(12):195-199.
9. World Health Organization. *The World Health Report 2002: Reducing Risks, Promoting Healthy Life*. World Health Organization; 2002.
10. Taylor BV, Palmer A, Simpson S, et al. Assessing possible selection bias in a national voluntary MS longitudinal study in Australia. *Multiple Sclerosis Journal*. 2013;19(12):1627-1631.

11. Balto JM, Ensari I, Hubbard EA, Khan N, Barnes JL, Motl RW. Individual and co-occurring SNAP risk factors: smoking, nutrition, alcohol consumption, and physical activity in people with multiple sclerosis. *International journal of MS care*. 2016;18(6):298-304.
12. Fitzgerald KC, Tyry T, Salter A, et al. Diet quality is associated with disability and symptom severity in multiple sclerosis. *Neurology*. 2018;90(1):e1.
13. Millen AE, Midthune D, Thompson FE, Kipnis V, Subar AF. The National Cancer Institute diet history questionnaire: validation of pyramid food servings. *American Journal of Epidemiology*. 2005;163(3):279-288.
14. Craig CL, Marshall AL, Sjoström M, et al. International physical activity questionnaire: 12-country reliability and validity. *Medicine and Science in Sports and Exercise*. 2003;35(8):1381-1395.
15. National Health and Medical Research Council. Australian dietary guidelines. *National Health and Medical Research Council, National Resource Management Ministerial Council*. 2013.
16. National Health and Medical Research Council. Australian guidelines to reduce health risks from drinking alcohol. *Working to build a healthy Australia*. 2009.
17. World Health Organization. WHO Expert Committee on Physical Status: The Use and Interpretation of Anthropometry. *Geneva, Switzerland: World Health Organization*. 1995.
18. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatrica Scandinavica*. 1983;67(6):361-370.
19. Marrie RA, Zhang L, Lix LM, et al. The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis. *Multiple Sclerosis and Related Disorders*. 2018;20:9-15.
20. Learmonth YC, Motl RW, Sandroff BM, Pula JH, Cadavid D. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. *BMC Neurology*. 2013;13(1):37.
21. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. *Archives of neurology*. 1989;46(10):1121-1123.

22. Pink B. Socio-economic indexes for areas (SEIFA). *Canberra: Australian Bureau of Statistics*. 2011.
23. Williamson EJ, Aitken Z, Lawrie J, Dharmage SC, Burgess JA, Forbes AB. Introduction to causal diagrams for confounder selection. *Respirology*. 2014;19(3):303-311.
24. Taylor KL, Hadgkiss EJ, Jelinek GA, et al. Lifestyle factors, demographics and medications associated with depression risk in an international sample of people with multiple sclerosis. *BMC Psychiatry*. 2014;14(1):327.
25. Rahe C, Unrath M, Berger K. Dietary patterns and the risk of depression in adults: a systematic review of observational studies. *European Journal of Nutrition*. 2014;53(4):997-1013.
26. Motl RW, McAuley E, Snook EM, Gliottoni RC. Physical activity and quality of life in multiple sclerosis: Intermediary roles of disability, fatigue, mood, pain, self-efficacy and social support. *Psychology, Health & Medicine*. 2009;14(1):111-124.
27. Bombardier C, Blake K, Ehde D, Gibbons L, Moore D, Kraft G. Alcohol and drug abuse among persons with multiple sclerosis. *Multiple Sclerosis Journal*. 2004;10(1):35-40.
28. Marck CH, Neate SL, Taylor KL, Weiland TJ, Jelinek GA. Prevalence of comorbidities, overweight and obesity in an international sample of people with multiple sclerosis and associations with modifiable lifestyle factors. *PLoS One*. 2016;11(2):e0148573.
29. Scott D, Happell B. The High Prevalence of Poor Physical Health and Unhealthy Lifestyle Behaviours in Individuals with Severe Mental Illness. *Issues in Mental Health Nursing*. 2011;32(9):589-597.
30. Wittenborn AK, Rahmandad H, Rick J, Hosseinichimeh N. Depression as a systemic syndrome: mapping the feedback loops of major depressive disorder. *Psychological medicine*. 2016;46(3):551-562.
31. McKay KA, Tremlett H, Fisk JD, et al. Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: A prospective multisite study. *Multiple Sclerosis Journal*. 2016;22(5):685-693.

32. Quesnel S, Feinstein A. Multiple sclerosis and alcohol: a study of problem drinking. *Multiple Sclerosis Journal*. 2004;10(2):197-201.
33. Bonnet F, Irving K, Terra J-L, Nony P, Berthezène F, Moulin P. Anxiety and depression are associated with unhealthy lifestyle in patients at risk of cardiovascular disease. *Atherosclerosis*. 2005;178(2):339-344.
34. Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. High frequency of adverse health behaviors in multiple sclerosis. *Multiple Sclerosis Journal*. 2009;15(1):105-113.
35. Becker H, Stuifbergen A. What Makes It So Hard? Barriers to Health Promotion Experienced by People With Multiple Sclerosis and Polio. *Family & Community Health*. 2004;27(1):75-85.

**Table 1.** Demographic characteristics of the 1,500 participants with multiple sclerosis included in the study.

Characteristic	Total		Missing Outcome or Exposure Data		Outcome and Exposure Data Available		<i>p</i> -value
	Mean	SD	Mean	SD	Mean	SD	
Age, years	56.0	11.2	56.2	11.8	56.0	11.1	0.80
SNAP score	2.7	0.90	2.7	0.87	2.7	0.90	0.16
	Median	IQR	Median	IQR	Median	IQR	<i>p</i> -value
Years since symptoms onset	13.0	10.0	13.0	10.0	13.0	10.0	0.44
Comorbidity number	3.0	3.0	3.0	3.0	3.0	3.0	0.88
	N	%	N	%	N	%	<i>p</i> -value
Female sex	1,192	79.5%	274	83.0%	918	78.5%	0.07
PDDS							
Mild (1-3)	569	37.9%	20	6.1%	549	46.9%	[ref]

Moderate (4-6)	412	27.5%	9	2.7%	403	34.4%	0.23
Severe (7-9)	214	14.3%	15	4.6%	199	17.0%	<b>0.04</b>
(missing)	305	20.3%	286	86.7%	19	1.6%	<b>&lt;0.001</b>
Type of MS at onset							
Relapse-onset MS	858	57.2%	28	8.5%	830	70.9%	[ref]
Progressive-onset MS	119	7.9%	6	1.8%	113	9.7%	0.33
(missing)	523	34.9%	296	89.7%	227	19.4%	<b>&lt;0.001</b>
Type of MS now							
Primary-progressive MS	97	8.7%	5	12.2%	92	8.6%	0.37
Relapsing-remitting MS	691	61.9%	23	56.1%	668	62.1%	[ref]
Secondary-progressive MS	167	15.0%	5	12.2%	162	15.1%	0.83
Progressive-relapsing MS	22	2.0%	1	2.4%	21	2.0%	0.76
Unsure	139	12.5%	7	17.1%	132	12.3%	0.33
Prevalent anxiety (HADS-A $\geq$ 8)	483	39.8%	20	44.4%	463	39.6%	0.51
Prevalent depression (HADS-D $\geq$ 8)	332	27.3%	10	22.2%	322	27.5%	0.43
Anxiety and depression	237	19.5%	6	13.3%	231	19.7%	0.29
Employed	479	39.6%	12	26.1%	467	40.1%	0.06
DMT use	756	62.4%	23	53.5%	733	62.8%	0.22

Prevalent fatigue (FSS $\geq$ 5 )	502	41.3%	23	48.9%	479	40.9%	0.28
Socioeconomic status							
Low	428	28.5%	102	30.9%	326	27.9%	0.14
Medium	413	27.5%	96	29.1%	317	27.1%	0.21
High	659	43.9%	132	40.0%	527	45.0%	[ref]
Depression treatment	353	23.5%	96	29.1%	257	22.0%	<b>0.01</b>
Anxiety treatment	204	13.6%	49	14.9%	155	13.3%	0.45

Abbreviations: DMT=Disease modifying therapies; IQR=Inter-quartile range; PDDS=Patient Determined Disease Steps; SD=Standard deviation. Differences in normally distributed continuous variables assessed by Student's t-test, while skewed continuous variables were assessed using Kruskal-Wallis rank sum test. Differences in categorical variables assessed by multinomial logistic regression. Results in boldface denote statistical significance.

**Table 2.** SNAP factor prevalence.

<b>SNAP factor</b>	<b>N</b>	<b>%</b>
Smoking		
At least one cigar/cigarette/pipe per day	156	10.4%
Less than one cigar/cigarette/pipe per day	1,344	89.6%
Diet		
Insufficient fruit and vegetable intake	1,340	89.9%
Sufficient fruit and vegetable intake	151	10.1%
Consumption of alcohol		
More than two standard drinks per day	256	17.1%
Two or less standard drinks per day	1,244	82.9%
Level of physical activity		
Low in the last week	707	47.1%
Moderate or high in the last week	793	52.9%
Body Mass Index		
Underweight, overweight or obese	883	61.0%
Healthy	564	39.0%

**Table 3.** Prevalence ratios of prevalent anxiety and depression (HADS  $\geq$  8).

	Prevalence Ratio (95% Confidence Interval)	
	Anxiety	Depression
Age (years)		
0-49	1.00 [ref]	1.00 [ref]
50-59	<b>0.80 (0.67, 0.94)</b>	1.19 (0.94, 1.51)
60-64	0.86 (0.71, 1.05)	1.27 (0.97, 1.67)
65+	<b>0.67 (0.55, 0.82)</b>	0.93 (0.70, 1.22)
<i>P-trend</i>	<b>&lt;0.001</b>	0.68
Sex (female)	<b>1.32 (1.09, 1.61)</b>	0.94 (0.76, 1.18)
Type of MS at onset		
Remitting-onset MS	1.00 [ref]	1.00 [ref]
Progressive-onset MS	1.17 (0.95, 1.45)	<b>1.34 (1.02, 1.75)</b>
Type of MS now		
Primary-progressive MS	1.00 [ref]	1.00 [ref]
Relapsing-remitting MS	0.94 (0.74, 1.21)	<b>0.70 (0.51, 0.95)</b>
Secondary-progressive MS	0.88 (0.65, 1.19)	1.09 (0.78, 1.53)
Progressive-relapsing MS	<b>1.51 (1.02, 2.23)</b>	1.20 (0.68, 2.13)
Unsure	0.73 (0.52, 1.03)	0.80 (0.55, 1.18)

PDDS

Mild disability	1.00 [ref]	1.00 [ref]
Moderate disability	<b>1.39 (1.20, 1.62)</b>	<b>2.07 (1.66, 2.59)</b>
Severe disability	1.01 (0.81, 1.24)	<b>2.28 (1.78, 2.91)</b>
<i>P-trend</i>	0.16	<b>&lt;0.001</b>
Prevalent fatigue	<b>1.80 (1.56, 2.06)</b>	<b>3.22 (2.63, 3.95)</b>
Years since symptom onset		
0-9	1.00 [ref]	1.00 [ref]
10-14	0.91 (0.76, 1.08)	1.01 (0.78, 1.30)
15-19	0.89 (0.73, 1.08)	1.17 (0.90, 1.53)
20+	0.71 (0.58, 0.88)	1.10 (0.85, 1.42)
<i>P-trend</i>	<b>0.002</b>	0.30
DMT use	1.07 (0.93, 1.24)	0.91 (0.76, 1.10)
Anxiety treatment	<b>2.05 (1.81, 2.33)</b>	<b>1.71 (1.39, 2.11)</b>
Depression treatment	<b>1.55 (1.35, 1.78)</b>	<b>2.06 (1.72, 2.46)</b>
Comorbidities		
0-2	1.00 [ref]	1.00 [ref]
3-5	<b>1.59 (1.33, 1.90)</b>	<b>1.65 (1.31, 2.09)</b>
6+	<b>2.07 (1.71, 2.50)</b>	<b>2.38 (1.85, 3.05)</b>
<i>P-trend</i>	<b>&lt;0.001</b>	<b>&lt;0.001</b>

Highest education level		
Primary School	1.00 [ref]	1.00 [ref]
Secondary School	1.46 (0.45, 4.75)	1.01 (0.31, 3.29)
Certificate or Diploma	1.46 (0.45, 4.74)	1.13 (0.35, 3.68)
Bachelor's Degree	1.31 (0.40, 4.26)	0.85 (0.26, 2.79)
Postgraduate Degree	1.24 (0.38, 4.08)	0.62 (0.18, 2.09)
<i>P-trend</i>	0.13	<b>0.002</b>
Employed	1.04 (0.91, 1.20)	<b>0.66 (0.54, 0.81)</b>
Socioeconomic status		
Low	1.00 [ref]	1.00 [ref]
Medium	0.96 (0.81, 1.15)	0.85 (0.67, 1.07)
High	0.87 (0.74, 1.03)	<b>0.72 (0.58, 0.89)</b>
<i>P-trend</i>	0.097	<b>0.003</b>
Rurality		
Major city	1.00 [ref]	1.00 [ref]
Regional	0.98 (0.85, 1.14)	1.14 (0.94, 1.37)
Remote	0.50 (0.14, 1.72)	0.76 (0.22, 2.64)

---

Abbreviations: DMT=Disease Modifying Therapies; MS=Multiple sclerosis; PDDS=Patient Determined Disease Steps; ref=Reference category.

Prevalence ratios estimated using log-binomial regression and are unadjusted.

---

Boldface values denote statistical significance ( $p < 0.05$ ).

Author Manuscript

**Table 4.** Association between SNAP protective factors & SNAP score and occurrence and severity of anxiety & depression.

	N	%	Anxiety		Depression	
			Prevalence Ratio	Symptom Severity (Adjusted $\beta_1$ )	Prevalence Ratio	Symptom Severity (Adjusted $\beta_1$ )
Non-smoker	1,344	89.6%	0.83 (0.68, 1.00)	<b>-1.33 (-2.10, -0.55)</b>	<b>0.75 (0.59, 0.94)</b>	<b>-1.12 (-1.76, -0.48)</b>
Healthy diet	151	10.1%	0.92 (0.72, 1.18)	-0.38 (-1.13, 0.36)	0.80 (0.57, 1.11)	<b>-0.81 (-1.42, -0.20)</b>
Non-hazardous consumption of alcohol	1,244	82.9%	1.01 (0.84, 1.22)	-0.19 (-0.80, 0.42)	<b>0.79 (0.63, 0.99)</b>	-0.32 (-0.82, 0.19)
Adequate physical activity	793	52.9%	0.98 (0.85, 1.14)	-0.13 (-0.62, 0.37)	<b>0.70 (0.57, 0.87)</b>	<b>-0.85 (-1.25, -0.44)</b>
Healthy BMI	564	39.0%	1.03 (0.89, 1.18)	0.03 (-0.44, 0.49)	0.94 (0.78, 1.14)	-0.16 (-0.54, 0.23)
SNAP score						
0/1	115	8.0%	1.00 [ref]	1.00 [ref]	1.00 [ref]	1.00 [ref]
2	490	34.0%	1.01 (0.79, 1.28)	-0.43 (-1.31, 0.46)	0.79 (0.62, 1.01)	<b>-0.81 (-1.53, -0.09)</b>
3	515	35.8%	1.03 (0.80, 1.31)	-0.37 (-1.25, 0.51)	<b>0.64 (0.49, 0.83)</b>	<b>-1.26 (-1.98, -0.54)</b>
4/5	320	22.2%	0.94 (0.71, 1.25)	-0.81 (-1.76, 0.13)	<b>0.57 (0.40, 0.81)</b>	<b>-1.57 (-2.34, -0.80)</b>
SNAP score (continuous)			0.98 (0.91, 1.06)	-0.20 (-0.45, 0.04)	<b>0.83 (0.75, 0.92)</b>	<b>-0.44 (-0.64, -0.24)</b>

*P Trend*

0.62

0.10

**<0.001**


**<0.001**

---

All models adjusted for age, sex, Patient-Determined Disease Steps score, depression or anxiety treatment, fatigue level, education level and socioeconomic status.

Boldface values denote statistical significance ( $p < 0.05$ ).

Author Manuscript



ane\_13132\_f1.jpg